192 related articles for article (PubMed ID: 18375353)
1. Targeted therapy for solid tumors: current status.
Zureikat AH; McKee MD
Surg Oncol Clin N Am; 2008 Apr; 17(2):279-301, vii-viii. PubMed ID: 18375353
[TBL] [Abstract][Full Text] [Related]
2. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
4. Cell signalling: growth factors and tyrosine kinase receptors.
Perona R
Clin Transl Oncol; 2006 Feb; 8(2):77-82. PubMed ID: 16632420
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy and elderly people: A review.
Daste A; Chakiba C; Domblides C; Gross-Goupil M; Quivy A; Ravaud A; Soubeyran P
Eur J Cancer; 2016 Dec; 69():199-215. PubMed ID: 27855351
[TBL] [Abstract][Full Text] [Related]
6. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
7. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
8. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma.
Ewing GP; Goff LW
Clin Colorectal Cancer; 2010 Oct; 9(4):219-23. PubMed ID: 20920993
[TBL] [Abstract][Full Text] [Related]
9. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics.
Kim MS; Zhong Y; Yachida S; Rajeshkumar NV; Abel ML; Marimuthu A; Mudgal K; Hruban RH; Poling JS; Tyner JW; Maitra A; Iacobuzio-Donahue CA; Pandey A
Mol Cell Proteomics; 2014 Nov; 13(11):2803-11. PubMed ID: 24895378
[TBL] [Abstract][Full Text] [Related]
12. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
14. [New biological treatments for lung cancer].
Zalcman G; Richard N; Bergot E
Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
[TBL] [Abstract][Full Text] [Related]
15. [Progress of targeted therapy related to K-ras mutation].
Li ZW; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
[No Abstract] [Full Text] [Related]
16. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
Penne K; Bohlin C; Schneider S; Allen D
Cancer Nurs; 2005; 28(6):481-6. PubMed ID: 16330971
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor.
Yang HH; Liu JW; Lee JH; Harn HJ; Chiou TW
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360896
[TBL] [Abstract][Full Text] [Related]
18. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors.
Lin NU; Winer EP
Breast Cancer Res; 2004; 6(5):204-10. PubMed ID: 15318926
[TBL] [Abstract][Full Text] [Related]
19. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
20. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
Montor WR; Salas AROSE; Melo FHM
Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]